SOST and osteoporosis: Subsequent studies have indicated that monoclonal antibodies to sclerostin such as romosozumab have been used in preclinical and clinical studies of osteoporosis with beneficial outcomes for bone mass and microstructure, and fractures risk reduction (4, 5, 8).